Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-01-2015 | Original Article – Clinical Oncology

Dynamics of fertility impairment and recovery after allogeneic haematopoietic stem cell transplantation in childhood and adolescence: results from a longitudinal study

Authors: C. Pfitzer, H. Orawa, M. Balcerek, T. Langer, U. Dirksen, P. Keslova, N. Zubarovskaya, F. R. Schuster, A. Jarisch, G. Strauss, A. Borgmann-Staudt

Published in: Journal of Cancer Research and Clinical Oncology | Issue 1/2015

Abstract

Purpose

Fertility impairment and recovery after haematopoietic stem cell transplantation (HSCT) have been reported in both sexes, but little is known about how they develop over time. Our aim was to describe the dynamics of fertility impairment and recovery after HSCT.

Methods

We retrieved treatment and fertility data for up to 12 years of 361 paediatric patients with malignant and non-malignant diseases from seven European centres. The patients had been treated with allogeneic HSCT between 2000 and 2005.

Results

Development of fertility impairment was observed in males (123/217, 56 %) after a median time of 2.6 years (range 0.1–11.4) and in females (82/144, 57 %) after 2.3 years (range 0.1–12.0) after HSCT. Different busulfan dosages had only a slight impact on the onset of fertility impairment (busulfan ≥16 mg/kg with a median time to fertility impairment of 2.9 vs. 3.9 years after busulfan <14 mg/kg). Recovery from fertility impairment was observed in 17 participants after a median time of 4.1 years (range 1–10.6) in females (10/144, 7 %) and 2.0 years (range 1–6.3) in males (7/217, 3 %) after fertility impairment first appeared.

Conclusions

In the light of the dynamics of fertility impairment and recovery in the HSCT patients reviewed, these patients should be counselled comprehensively regarding fertility preservation measures.

Anserini P, Chiodi S, Spinelli S, Costa M, Conte N, Copello F et al (2002) Semen analysis following allogeneic bone marrow transplantation. Additional data for evidence-based counselling. Bone Marrow Transplant 30(7):447–451. doi:10.1038/sj.bmt.1703651 PubMedCrossRef

Bakker B, Oostdijk W, Bresters D, Walenkamp MJ, Vossen JM, Wit JM (2004) Disturbances of growth and endocrine function after busulphan-based conditioning for haematopoietic stem cell transplantation during infancy and childhood. Bone Marrow Transplant 33(10):1049–1056. doi:10.1038/sj.bmt.1704481 PubMedCrossRef

Borgmann-Staudt A, Rendtorff R, Reinmuth S, Hohmann C, Keil T, Schuster FR et al (2012) Fertility after allogeneic haematopoietic stem cell transplantation in childhood and adolescence. Bone Marrow Transplant 47(2):271–276. doi:10.1038/bmt.2011.78 PubMedCrossRef

Couto-Silva AC, Trivin C, Thibaud E, Esperou H, Michon J, Brauner R (2001) Factors affecting gonadal function after bone marrow transplantation during childhood. Bone Marrow Transplant 28(1):67–75. doi:10.1038/sj.bmt.1703089 PubMedCrossRef

Das M, Shehata F, Son WY, Tulandi T, Holzer H (2012) Ovarian reserve and response to IVF and in vitro maturation treatment following chemotherapy. Hum Reprod 27(8):2509–2514. doi:10.1093/humrep/des143 PubMedCrossRef

European Group for Blood and Marrow Transplantation (2005). Statistical summary of EBMT Database. http://www.ebmt.org/4Registry/registry5.html (accessed May 2008)

Gnoth C, Godehardt E, Frank-Hermann P, Friol K, Tigges J, Freundl G (2005) Definition and prevalence of subfertility and infertility. Hum Reprod 20(5):1144–1147PubMedCrossRef

Green DM, Sklar CA, Boice JD Jr, Mulvihill JJ, Whitton JA, Stovall M et al (2009) Ovarian failure and reproductive outcomes after childhood cancer treatment: results from the Childhood Cancer Survivor Study. J Clin Oncol 27(14):2374–2381. doi:10.1200/JCO.2008.21.1839 PubMedCentralPubMedCrossRef

Howell SJ, Shalet SM (1998) Gonadal damage from chemotherapy and radiotherapy. Endocrinol Metab Clin North Am 27(4):927–943PubMedCrossRef

Howell SJ, Shalet SM (2002) Fertility preservation and management of gonadal failure associated with lymphoma therapy. Curr Oncol Rep 4(5):443–452PubMedCrossRef

Jantke A, Rendtorff R, Dittrich R, Muller A, Pfitzer C, Hohmann C et al (2012) Association between self-reported questionnaire data on fertility and results of hormone analyses in women after childhood cancer: a cross-sectional study. J Obstet Gynaecol Res 38(10):1254–1259. doi:10.1111/j.1447-0756.2012.01861 PubMedCrossRef

Illing S, Classen M (2005) Klinikleitfaden Pädiatrie. Urban und Fischer Verlag; 5. Auflage: 797

Meistrich ML V-SR, Lipshultz LI, Philadelphia (2001). Gonadal dysfunction. Cancer Principles and Practice of Oncology, 6th edn Lippincott; In: de Vita VT, Hellmann S, Rosenberg R (eds). 2923–2939

Mertens AC, Ramsay NK, Kouris S, Neglia JP (1998) Patterns of gonadal dysfunction following bone marrow transplantation. Bone Marrow Transplant 22(4):345–350. doi:10.1038/sj.bmt.1701342 PubMedCrossRef

Sherins RJ (1993) Gonadal dysfunction. In: de Vita VT, Hellmann S, Rosenberg R (eds) Cancer Principles and Practice of Oncology, 4th edn. Lippincott, Philadelphia, pp 2395–2404

Rovo A, Tichelli A, Passweg JR, Heim D, Meyer-Monard S, Holzgreve W et al (2006) Spermatogenesis in long-term survivors after allogeneic hematopoietic stem cell transplantation is associated with age, time interval since transplantation, and apparently absence of chronic GvHD. Blood 108(3):1100–1105. doi:10.1182/blood-2006-01-0176 PubMedCrossRef

Salooja N, Szydlo RM, Socie G, Rio B, Chatterjee R, Ljungman P et al (2001) Pregnancy outcomes after peripheral blood or bone marrow transplantation: a retrospective survey. Lancet 358(9278):271–276PubMedCrossRef

Sanders JE, Buckner CD, Leonard JM, Sullivan KM, Witherspoon RP, Deeg HJ et al (1983) Late effects on gonadal function of cyclophosphamide, total-body irradiation, and marrow transplantation. Transplantation 36(3):252–255PubMedCrossRef

Socie G, Salooja N, Cohen A, Rovelli A, Carreras E, Locasciulli A et al (2003) Nonmalignant late effects after allogeneic stem cell transplantation. Blood 101(9):3373–3385. doi:10.1182/blood-2002-07-2231 PubMedCrossRef

Teinturier C, Hartmann O, Valteau-Couanet D, Benhamou E, Bougneres PF (1998) Ovarian function after autologous bone marrow transplantation in childhood: high-dose busulfan is a major cause of ovarian failure. Bone Marrow Transplant 22(10):989–994. doi:10.1038/sj.bmt.1701483 PubMedCrossRef

van Rooij IA, Tonkelaar I, Broekmans FJ, Looman CW, Scheffer GJ, de Jong FH et al (2004) Anti-mullerian hormone is a promising predictor for the occurrence of the menopausal transition. Menopause 11(6 Pt 1):601–606PubMedCrossRef

Vatanen A, Wilhelmsson M, Borgstrom B, Gustafsson B, Taskinen M, Saarinen-Pihkala UM et al (2014) Ovarian function after allogeneic hematopoietic stem cell transplantation in childhood and adolescence. Eur J Endocrinol 170(2):211–218. doi:10.1530/EJE-13-0694 PubMedCrossRef

Title: Dynamics of fertility impairment and recovery after allogeneic haematopoietic stem cell transplantation in childhood and adolescence: results from a longitudinal study
Authors: C. Pfitzer
H. Orawa
M. Balcerek
T. Langer
U. Dirksen
P. Keslova
N. Zubarovskaya
F. R. Schuster
A. Jarisch
G. Strauss
A. Borgmann-Staudt
Publication date: 01-01-2015
Publisher: Springer Berlin Heidelberg
Published in: Journal of Cancer Research and Clinical Oncology / Issue 1/2015
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-014-1781-5

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Dynamics of fertility impairment and recovery after allogeneic haematopoietic stem cell transplantation in childhood and adolescence: results from a longitudinal study

Abstract

Purpose

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2015

Epirubicin combined with oxaliplatin and 5-day continuous infusion of 5-fluorouracil as a first-line treatment for metastatic gastric cancer: treatment outcomes and analysis of prognostic factors

The efficacy of EGFR gene mutation testing in various samples from non-small cell lung cancer patients: a multicenter retrospective study

CBB1003, a lysine-specific demethylase 1 inhibitor, suppresses colorectal cancer cells growth through down-regulation of leucine-rich repeat-containing G-protein-coupled receptor 5 expression

Vascular endothelial growth factor (VEGF) polymorphism and increased risk of epithelial ovarian cancer

Enhanced antitumor efficacy of a novel oncolytic adenovirus combined with temozolomide in the treatment of melanoma in vivo

Efficacy and safety of percutaneous radiofrequency ablation versus surgical resection for small hepatocellular carcinoma: a meta-analysis of 23 studies

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page